Oncurious NV is an oncology company focused on the development of innovative medicines for the treatment of pediatric brain tumors.
In February 2013, a paper in Cell (Cell, 152, 1065-76, 2013) highlighted for the first time that PlGF – placental growth factor – plays a vital role in the brain. Its expression is required for the growth and spread of medulloblastoma, a rare, life-threatening brain tumor that mainly affects children. The paper was based on pre-clinical research conducted by Prof. Rakesh Jain from the Massachusetts General Hospital at Harvard (Boston) and the research team of Prof. Peter Carmeliet from VIB/ KU Leuven.
Oncurious has initiated a Phase I/IIa clinical program with TB-403, a humanized monoclonal antibody against PlGF, for the treatment of medulloblastoma, The study aims at recruiting a minimum of 27 patients, with first results expected to be reported in 2017.
Oncurious NV was incorporated in April 2015. Its main shareholders are ThromboGenics NV, an integrated biopharmaceutical company focused on developing and commercializing ophthalmic medicines, and VIB, a leading life sciences institute in Flanders (Belgium).
BioInvent International AB, a research-based pharmaceutical company focused on the discovery and development of innovative antibody-based drugs against cancer, will act as a co-development partner for this project.
Click here to view the latest corporate presentation.